Strategic Partnerships Chembio has merged with or is affiliated to Biosynex and has recently acquired assets from Qualigen. This indicates a strategic pivot toward expanded distribution, OEM collaborations, and co-developed rapid diagnostics, presenting sales opportunities in bundled solutions, cross-sell of platforms, and access to broader global networks.

Expanded Financing Recent financing activity including a 1.8 million CARB-X grant and prior public offerings suggest government and grant-backed support for rapid diagnostics. This creates openings for grant-aligned procurement, funded pilot programs, and long-term contracts for fast-start deployments in public health and clinics.

DPP Platform Value Chembio’s DPP rapid test platform enables multiplexed results and quick on-site decisions. This positions the company to upsell to health networks seeking decentralized testing, including HIV, syphilis, and typhoid initiatives, as well as integration with portable readers for point-of-care programs.

Global Reach Products are sold globally through direct and distributor channels to hospitals, clinics, laboratories, and government agencies. This broad footprint suggests potential for channel partnerships, regional distribution deals, and government-facing tenders in regions prioritizing rapid diagnostics.

Clinical And Public Health Demand Focusing on infectious diseases and rapid results aligns with ongoing demand in STI screening, HIV/syphilis programs, and typhoid testing. There are opportunities to pursue expansions into hospital networks, public health programs, and urgent-response testing initiatives via existing and new customers.